Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia最新文献

Multiple intracranial infectious aneurysms in a case of endocarditis. Intravascular management. 心内膜炎并发多发颅内感染性动脉瘤1例。血管内管理。

IF 2.2

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2026-04-30 DOI: 10.37201/req/139.2025

Monique Boukobza, Sylvie Lariven, Jean-Pierre Laissy

引用次数: 0

Human herpesvirus type 7 and bone marrow disorders: a new association to consider in relation with a case report. 人疱疹病毒7型与骨髓疾病：与病例报告有关的新联系

IF 2.2

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2026-04-17 DOI: 10.37201/req/157.2026

Agustín Estévez, Miguel López-Esteban, Pilar Catalán, Lara Mesones, Belén Padilla, Roberto Alonso, Patricia Muñoz

引用次数: 0

Underdiagnosed brain abscess and meningitis caused by Parvimonas micra in an immunocompetent host: an idiopathic case. 免疫功能正常的小微单胞菌引起的未确诊脑脓肿和脑膜炎：一个特发性病例。

IF 2.2

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2026-04-17 DOI: 10.37201/req/146.2026

Laura Andrés-Eslava, Violeta Artal-Muñoz, Remedios Guna-Serrano, Concepción Gimeno-Cardona

引用次数: 0

[From cutaneous abscess to ventriculitis caused by Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus]. [从皮肤脓肿到脑室炎由潘通-瓦伦丁白细胞素阳性耐甲氧西林金黄色葡萄球菌引起]。

IF 2.2

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2026-04-17 DOI: 10.37201/req/149.2026

Marina Pintor-Rey, Alejandro Carrasco-González, Clara Lejarraga-Cañas, Rosa Gutierrez-Rico, Beatriz Mateos-Goñi, Laura Guío-Carrión

引用次数: 0

Situation and questions regarding the practice of blood cultures in paediatric patients: an opinion paper. 儿科患者血液培养实践的情况和问题：一份意见文件。

IF 2.2

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2026-04-17 DOI: 10.37201/req/159.2026

Almudena Burillo, Agustín Estévez, Martha Kestler, María Jesús Pérez-Granda, Patricia Muñoz, Emilio Bouza

{"title":"Situation and questions regarding the practice of blood cultures in paediatric patients: an opinion paper.","authors":"Almudena Burillo, Agustín Estévez, Martha Kestler, María Jesús Pérez-Granda, Patricia Muñoz, Emilio Bouza","doi":"10.37201/req/159.2026","DOIUrl":"https://doi.org/10.37201/req/159.2026","url":null,"abstract":"The collection and interpretation of blood cultures in paediatric patients require specific considerations that make simple extrapolation from adult recommendations inappropriate. In recent years, the incidence and aetiology of paediatric bacteraemia have evolved, influenced by vaccination programmes, improved infection prevention strategies, and increasing clinical complexity, particularly in neonatal, oncohaematological, and intensive care settings. Clinical guidelines recommend blood cultures in neonates and infants with fever without a focus in children with sepsis or shock, with immunosuppression, suspected endovascular infection, meningitis, osteoarticular infections, or severe community-acquired pneumonia. Conversely, routine use is discouraged in clearly viral infections and in mild cases in previously healthy children. Available evidence consistently identifies the volume of blood inoculated as the main determinant of diagnostic performance, and this should be adjusted for age and weight. Obtaining one or two appropriately indicated peripheral blood culture sets, together with proper antisepsis, reduces contamination and improves clinical interpretation. Whenever feasible, both aerobic and anaerobic bottles should be included, given their complementary diagnostic yield. There is no robust evidence that paediatric bottles with smaller broth volumes provide substantial advantages over standard bottles when adequate blood volumes are inoculated. Importantly, no evidence demonstrates that the type of bottle or automated system used influences hospital stay, clinical outcomes, or mortality. This article presents an evidence-informed perspective that integrates current literature with expert clinical judgment, derived from more than four decades of experience at a high-complexity tertiary-care hospital.","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147730414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidence of surgical site infection surveillance in hysterectomies and related risk factors: a prospective cohort study. 子宫切除术手术部位感染监测的发生率及相关危险因素：一项前瞻性队列研究。

IF 2.2

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2026-03-27 DOI: 10.37201/req/152.2025

Diego Rodríguez-Villar, Maria Pilar Cárdenas-Soriano, Nieves Climent-Martínez, Ana María Pedraza-Flechas, Sergio Rodríguez-Villar, Patricia Zamorano-Méndez, María Concepción Villar-Del-Campo, Jesús María SanRomán-Montero, Manuel Durán-Poveda, Gil Rodríguez-Caravaca

{"title":"Incidence of surgical site infection surveillance in hysterectomies and related risk factors: a prospective cohort study.","authors":"Diego Rodríguez-Villar, Maria Pilar Cárdenas-Soriano, Nieves Climent-Martínez, Ana María Pedraza-Flechas, Sergio Rodríguez-Villar, Patricia Zamorano-Méndez, María Concepción Villar-Del-Campo, Jesús María SanRomán-Montero, Manuel Durán-Poveda, Gil Rodríguez-Caravaca","doi":"10.37201/req/152.2025","DOIUrl":"10.37201/req/152.2025","url":null,"abstract":"Background: Healthcare-associated infections (HAIs) represent the most common adverse event among hospitalized patients. The aim of this study was to assess Surgical Site Infection (SSI) incidence in hysterectomies, and the related risk factors.Materials and methods: A prospective cohort study on patients undergoing abdominal or vaginal hysterectomy was carried out. We assessed the incidence of SSIs according to CDC/NHSN criteria. Patients' demographic and clinical characteristics were described. Univariate and multivariate analyses were conducted to find independently associated risk factors for SSI. The association between risk factors and SSI incidence was assessed by reference to the adjusted odds ratio (OR).Results: The study covered a total of 1,154 women who underwent abdominal (47.7%) or vaginal (52.3%) hysterectomy. Patients' overall mean age was 54.7 years (SD=13.2). Overall SSI incidence at the end of follow-up was 2.5% (n=29), 1.9% in abdominal hysterectomies and 3.4% in vaginal hysterectomies (p>0.05). We found diabetes mellitus (OR: 2.9, 95% CI: 1.1-8.0, p=0.04) and cancer (OR: 3.7, 95% CI: 1.4-9.6, p=0.007) independently associated with SSI incidence.Conclusions: Vaginal hysterectomies accounted for 52.3%. Global incidence of SSI reached 2.5% and was in the lowest rank of the published evidence. Diabetes mellitus and cancer were risk factors related to SSIs.","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"135-142"},"PeriodicalIF":2.2,"publicationDate":"2026-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13071773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147534915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Bacteremia secondary to Campylobacter jejuni pancolitis in an immunocompetent patient]. [免疫功能正常患者空肠弯曲杆菌性结肠炎继发菌血症]。

IF 2.2

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2026-03-19 DOI: 10.37201/req/135.2025

Alfredo Sejas-Claros, Marta Cano-Pérez, Belén Francisca Sánchez-Borge, Belén Lorenzo-Vidal, José María Eiros-Bouza

引用次数: 0

Intravenous non-specific immunoglobulins as adjunctive therapy for invasive Streptococcus pyogenes infection: an eleven-year retrospective study. 静脉注射非特异性免疫球蛋白作为侵袭性化脓性链球菌感染的辅助治疗：一项11年的回顾性研究。

IF 2.2

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2026-03-19 DOI: 10.37201/req/125.2026

Laura Caeiro-Martínez, David Brandariz-Núñez, María Sandra Albiñana-Pérez, Enrique Alemparte-Pardavila, Mónica Mourelo-Fariña, José María Gutiérrez-Urbón, Luis Margusino-Framiñán

{"title":"Intravenous non-specific immunoglobulins as adjunctive therapy for invasive Streptococcus pyogenes infection: an eleven-year retrospective study.","authors":"Laura Caeiro-Martínez, David Brandariz-Núñez, María Sandra Albiñana-Pérez, Enrique Alemparte-Pardavila, Mónica Mourelo-Fariña, José María Gutiérrez-Urbón, Luis Margusino-Framiñán","doi":"10.37201/req/125.2026","DOIUrl":"10.37201/req/125.2026","url":null,"abstract":"Introduction: Adjunctive intravenous non-specific immunoglobulin (IVIG) is used in the management of streptococcal toxic shock syndrome, although supporting evidence remains limited. The primary objective of this study was to describe the use of IVIG in patients with invasive Streptococcus pyogenes infection.Materials and methods: We conducted a retrospective observational study over 11 years, including patients diagnosed with invasive S. pyogenes infection who received at least one dose of IVIG as adjunctive therapy.Results: Twenty-three patients were included, with a mean age of 63.2 ± 16.3 years; 47.8% were male. Most patients (73.9%) developed septic shock and STSS, requiring admission to intensive care units. The mean Sequential Organ Failure Assessment (SOFA) score was 9.1 ± 4.9. High-dose IVIG (2.0 ± 0.2 g/kg) was administered promptly, with a mean time to first infusion of 0.26 ± 0.47 days from admission. In-hospital mortality was 21.7% overall and 29.4% among STSS patients. Non-survivors had significantly higher disease severity and were more likely to develop hepatic dysfunction and require continuous renal replacement therapy (CRRT). Two patients (8.7%) experienced IVIG-related adverse events, both of which were mild.Conclusion: Early and standardized high-dose IVIG administration, in combination with prompt targeted antibiotic therapy and intensive supportive care, was associated with mortality rates similar to, or lower than, those previously reported. Initial disease severity, hepatic dysfunction, and need for CRRT were identified as predictors of mortality. IVIG demonstrated a favorable safety profile.","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"125-134"},"PeriodicalIF":2.2,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13071772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147488801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delafloxacin: what does a new fluoroquinolone offer? 德拉沙星：一种新的氟喹诺酮类药物提供了什么？］

IF 2.2

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2026-03-11 DOI: 10.37201/req/151.2026

Emilia Cercenado, Oscar Murillo

{"title":"Delafloxacin: what does a new fluoroquinolone offer?","authors":"Emilia Cercenado, Oscar Murillo","doi":"10.37201/req/151.2026","DOIUrl":"10.37201/req/151.2026","url":null,"abstract":"Delafloxacin is a novel anionic fluoroquinolone with a different chemical structure from currently marketed fluoroquinolones, which gives it distinct physicochemical characteristics, being active in both acidic and neutral environments. Delafloxacin is also unique in showing a dual-targeted equipotent inhibition of the essential bacterial enzymes DNA gyrase and topoisomerase IV, which may explain the very low frequencies of spontaneous mutations in vitro. It shows potent in vitro activity against a broad spectrum of Gram-negative bacteria, including some fluoroquinolone-resistant strains, and increased efficiency against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus, although it is always necessary to determine the in vitro activity of delafloxacin against fluoroquinolone-resistant isolates. Delafloxacin exhibits linear pharmacokinetics, a wide volume of distribution, and a concentration-dependent pattern of antimicrobial killing, a property that allows the use of high doses for greater effectiveness in some difficult-to-treat infections. Delafloxacin is available for clinical use in oral and intravenous formulations and has been approved for the treatment of acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia based on the results from phase II and III clinical trials. Overall, delafloxacin has been well tolerated and has a low profile of drug-drug interactions. Its activity in local acidic environments and biofilms could play a role in the treatment of biofilm-related infections such as osteoarticular and medical device-associated infections, and due to its broad spectrum, it can also be useful in polymicrobial infections. Delafloxacin is an interesting new addition to the therapeutic arsenal against common and difficult-to-treat infections.","PeriodicalId":94198,"journal":{"name":"Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia","volume":" ","pages":"104-124"},"PeriodicalIF":2.2,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13071785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147438696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Visceral leishmaniasis in a multiple sclerosis patient: a rare complication of fingolimod-induced lymphopenia. 多发性硬化症患者内脏利什曼病：芬戈莫诱导淋巴细胞减少症的罕见并发症。

IF 2.2

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia Pub Date : 2026-03-09 DOI: 10.37201/req/122.2025

Alba García-Alabarce, Elena Cornejo-Calvo, Adolfo de Salazar-González, Emilio Guirao-Arrabal

引用次数: 0